CARES-009 Trial: Evaluating Camrelizumab and Rivoceranib for Resectable Hepatocellular Carcinoma

Surgical resection remains the gold standard for early-stage hepatocellular carcinoma, yet the persistent threat of recurrence often undermines long-term survival. The emergence of perioperative immunotherapy is now challenging the traditional “surgery-first” paradigm, offering a potential pathway to significantly extend the window of event-free survival.

Key Clinical Takeaways:

• Perioperative camrelizumab plus rivoceranib more than doubled event-free survival (EFS) compared to surgery alone, reaching 42.1 months versus 19.4 months.
• The treatment protocol utilizes a “sandwich” approach: two cycles of neoadjuvant therapy, followed by surgical resection and concluding with adjuvant therapy.
• The trial targeted patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence, specifically those within CNLC stages Ib-IIIa.

The clinical gap in treating hepatocellular carcinoma (HCC) has long been the high rate of recurrence following curative resection. While surgery removes the primary tumor, it often fails to address micrometastases or the underlying pro-tumorigenic environment of the liver. This creates a critical demand for therapies that can reduce tumor burden before the operation and eliminate residual disease afterward. The CARES-009 trial addresses this by evaluating a combined immunotherapy and anti-angiogenic approach to transform the standard of care from a single surgical event into a comprehensive perioperative strategy.

The Architecture of the CARES-009 Clinical Trial

The CARES-009 study was designed as a multicentre, open-label, randomised, phase 2/3 trial conducted across 16 hospitals in China. The trial enrolled 294 patients, the vast majority of whom were male (87%) and of Han Chinese descent (99%). To ensure a rigorous assessment of efficacy, patients were randomly assigned in a 1:1 ratio to either the perioperative therapy group or the surgery-alone group, with stratification based on hepatitis B virus (HBV) infection status and China Liver Cancer Staging (CNLC) stage.

The eligibility criteria were precise, focusing on patients with resectable HCC classified as CNLC stage Ib-IIIa. A critical exclusion factor was the presence of Vp4 portal vein tumour thrombosis, which typically indicates a more advanced disease state and a different prognostic trajectory. This focus on intermediate to high-risk patients allows the trial to isolate the impact of immunotherapy on those most likely to suffer from recurrence. For clinicians managing these complex cases, coordinating care between specialized surgical oncologists and immunotherapy experts is essential to timing the neoadjuvant phase correctly.

Analyzing Event-Free Survival and Clinical Efficacy

According to the data published in The Lancet, the primary endpoint of event-free survival (EFS) showed a stark divergence between the two cohorts. The perioperative group achieved an EFS of 42.1 months, a substantial increase over the 19.4 months observed in the surgery-alone group. This suggests that the combination of camrelizumab and rivoceranib effectively modifies the disease course, potentially by priming the immune system to recognize tumor antigens before surgery and suppressing the regrowth of occult lesions post-operatively.

The pharmacological synergy here involves combining a PD-1 inhibitor (camrelizumab) with an anti-angiogenic agent (rivoceranib). This dual-action approach targets both the immune evasion mechanisms of the tumor and its blood supply, which is a hallmark of HCC pathogenesis. Because these therapies can introduce systemic toxicities, patients require rigorous monitoring. This proves highly recommended that patients undergoing such intensive regimens be managed within comprehensive hepatology clinics to ensure liver function is preserved throughout the perioperative window.

Methodological Considerations and Regulatory Hurdles

Despite the impressive EFS numbers, the trial’s open-label design introduces certain vulnerabilities. The investigators assessing the primary endpoint were not masked to the group assignments, which can introduce observer bias in the interpretation of imaging and recurrence events. In the world of high-stakes oncology, the transition from a phase 2/3 trial to a global standard of care requires the mitigation of such biases through double-blind, placebo-controlled validations.

the study population was predominantly Han Chinese, which may limit the immediate generalizability of the results to other ethnic populations with different underlying etiologies of HCC, such as those driven more by NASH or alcohol-related cirrhosis in Western cohorts. As these findings move toward regulatory review, pharmaceutical providers and clinical sites must ensure strict adherence to international trial protocols. Many institutions are currently engaging healthcare compliance attorneys to audit their clinical trial frameworks to meet the stringent demands of the FDA, and EMA.

The intention-to-treat population analysis provides a realistic view of the drug’s impact, but the “as-treated” population analysis for safety is where the true morbidity profile of the combination therapy is revealed. Balancing the significant gain in EFS against the potential for immune-related adverse events remains the central challenge for the prescribing physician.

The results of CARES-009 mark a pivotal shift in the management of resectable hepatocellular carcinoma, suggesting that the window around surgery is the most opportunistic time to deploy aggressive immunotherapy. While the lack of masking in the trial warrants a cautious interpretation, the magnitude of the EFS improvement is difficult to ignore. The future of HCC treatment likely lies in this integrated, multi-modal approach, moving away from isolated surgical interventions toward a continuous cycle of systemic and local control. To explore whether these emerging protocols are appropriate for a specific clinical profile, patients and providers should consult with vetted oncology specialists through our global medical directory.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.